Skip to content

Research Protocol on the Interventional Effects of Targeted rTMS Based on Different Targets and Stimulation Modalities on Cognitive Function in Alzheimer's Disease Patients

Research Protocol on the Interventional Effects of Targeted rTMS Based on Different Targets and Stimulation Modalities on Cognitive Function in Alzheimer's Disease Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123738
Enrollment
Unknown
Registered
2026-04-29
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

Sham stimulation group:Administer sham stimulation to the patient
20Hz-DLPFC group:20Hz Transcranial Magnetic Stimulation Targeting the DLPFC
iTBS-DLPFC group:Intracranial Transcranial Brain Stimulation Targeting the DLPFC
20Hz-Personalized Target group:20Hz transcranial magnetic stimulation targeting personalized sites determined based on network connectivity

Sponsors

Huanhu Hospital, Tianjin, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 50 - 85 years old; meets the diagnostic criteria for AD proposed by NIA-AA; 2. The patient's Mini-Mental State Examination (MMSE) score is between 10 and 27; 3. Mild to moderate AD patients, i.e., Clinical Dementia Rating (CDR) <= 2 points; 4. The patient and their family members have the capacity for civil conduct, and are capable of understanding and signing the consent form.

Exclusion criteria

Exclusion criteria: 1. Has a history of epilepsy or other neurological disorders; 2. Has severe depression with a score of >20 on the 24-item Hamilton Depression Rating Scale (Hamilton Depression Scale, HAMD); 3. Has visual or auditory impairment; 4. Has any serious chronic systemic disease history, brain injury history, history of alcohol or drug abuse; 5. Has any contraindications for TMS.

Design outcomes

Primary

MeasureTime frame
MMSE and MoCA scales;

Secondary

MeasureTime frame
Electroencephalogram (EEG) indicators;Nuclear magnetic indicators;Blood biomarker;

Countries

China

Contacts

Public ContactPan Wang

Tianjin Huanhu Hospital

wpaofeier@163.com+86 22 5906 5221

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026